---
document_datetime: 2025-04-08 12:00:39
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/evrenzo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: evrenzo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.2988454
conversion_datetime: 2025-12-31 02:09:15.226377
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Evrenzo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10955 /202312  | Periodic Safety Update EU Single assessment - roxadustat                                                                   | 25/07/2024                          | 19/09/2024                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10955/202312. |
| IAIN/0009            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 15/04/2024                          | 23/05/2024                                  | Annex II and PL                  |                                                                                                                                            |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/10955 /202306   | Periodic Safety Update EU Single assessment - roxadustat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 11/01/2024   | n/a        | PRAC Recommendation - maintenance   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------------------|
| PSUSA/10955 /202212   | Periodic Safety Update EU Single assessment - roxadustat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 06/07/2023   | n/a        | PRAC Recommendation - maintenance   |
| IB/0006/G             | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes | 02/06/2023   | 23/05/2024 | SmPC, Labelling and                 |
| IB/0004               | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 27/02/2023   | n/a        |                                     |

<div style=\"page-break-after: always\"></div>

|                     | re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                   |                                                                                                                                                                                                                                                                                                                      |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10955 /202206 | Periodic Safety Update EU Single assessment - roxadustat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 12/01/2023 | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                    |
| PSUSA/10955 /202112 | Periodic Safety Update EU Single assessment - roxadustat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 21/07/2022 | 30/09/2022 | SmPC              | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10955/202112.                                                                                                                                                                           |
| II/0002             | Update of section 4.8 of the SmPC in order to add dermatitis exfoliative generalised (DEG) to the list of adverse drug reactions (ADRs) with frequency unknow based on post-marketing data and literature. In addition, the MAH took the opportunity to amend the Annex IIB in order to reflect the fact that restricted prescription applies. Furthermore, the MAH took the opportunity to implement editorial changes to the SmPC C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 23/06/2022 | 30/09/2022 | SmPC and Annex II | Update of section 4.8 of the SmPC in order to add dermatitis exfoliative generalised (DEG) to the list of adverse drug reactions (ADRs) with frequency unknow based on post-marketing data and literature. PL was updated accordingly. For more information, please refer to the Summary of Product Characteristics. |